Oncopharmpod
Bad News For Belantamab-Mafodotin And Atezolizumab's Bladder Cancer Indication
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:13:54
- More information
Informações:
Synopsis
Recent voluntary withdrawals from the US market of belantamab-mafodotin and atezolizumab's indication for bladder cancer have us weighing (again) the pros & cons of the accelerated approval program. Also, FDA approves the 1st fecal transplant product.
